Myelofibrosis Treatment Market: A Well-Defined Technological Growth Map With An Impact-Analysis

Myelofibrosis, also known as osteomyelofibrosis, is a myeloproliferative condition characterised by the proliferation of aberrant hematopoietic stem cell clones. Myelofibrosis is an uncommon form of persistent leukaemia that compromises the bone marrow's ability to make blood. The National Institute of Health (NIH) has classified it as a rare disease since the prevalence of myelofibrosis in the United Kingdom is as low as 0.5 cases per 100,000 people. Myelofibrosis is caused by a genetic abnormality in bone marrow stem cells.

The illness is reported to develop primarily in adults over the age of 50 and exhibits no symptoms in the early stages. Myelofibrosis is commonly accompanied with symptoms such as weakness, fatigue, anaemia, splenomegaly (spleen enlargement), and gout. However, the disease advances slowly, and only 10% of patients acquire acute myeloid leukaemia. Myelofibrosis treatment options are mostly focused on preventing the problems associated with low blood count and splenomegaly.

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

Because myelofibrosis is a non-curable condition, therapy options are primarily based on apparent symptoms of the disease. Supportive therapies like as chemotherapy and radiation therapy are used to treat the early stages of myelofibrosis. However, due to a paucity of disease-modifying drugs, there are significant unmet requirements in the myelofibrosis therapeutic market. Ruxolitinib's approval as a JAK1/JAK2 inhibitor in 2011 is seen as a milestone in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis has significant market potential, but the high cost of therapy is expected to hinder the segment's growth.